Medpace (MEDP) revenue breakdown
By product, Oncology is the largest at 30% of fiscal 2025 revenue; Other grew fastest, 29% a year over 7 years.
Revenue by product
Fiscal years, as Medpace reports them in its 10-K filings; fiscal 2025 total $2.5B.
| Products | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oncology | — | — | $189M | $257M | $298M | $363M | $468M | $587M | $651M | $748M | 30% |
| Other | — | — | $125M | $139M | $126M | $160M | $245M | $377M | $458M | $745M | 29% |
| Metabolic | — | — | $164M | $196M | $215M | $267M | $297M | $405M | $431M | $409M | 16% |
| AVAI | — | — | $54M | $92M | $88M | $122M | $158M | $160M | $182M | $255M | 10% |
| Central Nervous System | — | — | $95M | $91M | $95M | $120M | $175M | $194M | $230M | $239M | 9% |
| Cardiology | — | — | $77M | $86M | $103M | $111M | $118M | $163M | $156M | $135M | 5% |
| Direct Service Revenue | — | $386M | — | — | — | — | — | — | — | — | — |
| Direct Service Revenue | $371M | — | — | — | — | — | — | — | — | — | — |
| Reimbursed Out of Pocket Revenue | $51M | — | — | — | — | — | — | — | — | — | — |
| Reimbursed Out of Pocket Revenue | — | $50M | — | — | — | — | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for MEDP.
Open MEDP in InvestinglyQuestions
Where does Medpace make its money?
In fiscal 2025, by product: Oncology $748M, Other $745M, Metabolic $409M, AVAI $255M, Central Nervous System $239M.
From Medpace's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.